Metastatic HER2+ Breast Cancer: Current Strategies and Ongoing Trials

Opinion
Video

Experts discuss the CLEOPATRA trial outcomes, taxane nuances, and evolving strategies in first-line treatment. They review practical considerations and ongoing trials and dive into the dynamic landscape of managing metastatic HER2+ breast cancer, anticipating transformative developments.

This is a video synopsis/summary of a Peer Exchange involving Joyce O’Shaughnessy, MD; Priyanka Sharma, MD; Claudine Isaacs, MD; Heather McArthur, MD; and Hope S. Rugo, MD, FASCO.

O’Shaughnessy and Rugo discuss the first-line treatment landscape for metastatic HER2-positive breast cancer, focusing on the CLEOPATRA trial’s impact. CLEOPATRA demonstrated significant improvements in progression-free survival and overall survival by adding pertuzumab to docetaxel and trastuzumab. The long-term follow-up, 8 years post treatment, maintains these benefits. McArthur emphasizes the practical use of paclitaxel versus docetaxel based on tolerability. The conversation touches on the challenges of managing de novo metastatic disease and the role of hormone therapy. Ongoing trials such as PATINA and PEARL are expected to provide further insights into optimizing treatment strategies. Isaacs highlights the importance of considering patients’ quality of life and discusses ongoing Translational Breast Cancer Research Consortium trials exploring treatment cessation for those on long-term maintenance therapy. The discussion sets the stage for understanding the evolving landscape and sequencing of treatments in patients with metastatic HER2-positive breast cancer.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.

Related Videos
Video 2 - "Navigating Glioblastoma Imaging: The Patient Journey from Diagnosis to Treatment "
Video 1 - "Neuroimaging of Glioblastoma"
Video 11 - "Pioneering Breakthroughs in HCC Treatment"
Video 18 - "Reflecting on Differentiated Thyroid Cancer: Final Insights"
Video 17 - "Phase 2 ATLEP Trial Results"
Video  10 -"Real-World Evidence on Second-Line Therapy Selection and Outcomes"
Video  9 - "Additional Second-Line Treatments for HCC"
Video 16 - "Neoadjuvant Approach in RAI-R-DTC"
Video 15 - "Addressing Unmet Needs and Challenges in RAI-R-DTC Treatment"
Video 8 - "The Evolving Landscape of Second-Line Therapies in HCC Management"
Related Content